Get started
Evofem Biosciences, Inc.Evofem Biosciences, Inc.Evofem Biosciences, Inc.

Evofem Biosciences, Inc.

No trades
See on Supercharts
Overview
Financials
News Ideas Discussions Technicals Seasonals

EVFM fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate), a hormone-free vaginal gel and EVO100, an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

EVFM does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company